Molecular markers and prognosis of myelofibrosis in the genomic era: a meta-analysis

Molecular markers are important in guiding treatment and predicting outcome in the genomic era. Meta-analysis of molecular markers in myelofibrosis through a search of PubMed and Medline to October 31, 2017 was performed. More than three studies compared overall survival (OS) and leukemia-free survival (LFS) were eligible. A total of 16 studies were included. HR for OS were as follows: IDH 2.65 (95%CI 1.66-4.21), SRSF2 2.12 (1.18-3.79), HRM 2.11 (1.70-2.61), ASXL1 1.92 (1.60-2.32), EZH2 1.88 (1.32-2.67), JAK2 1.41 (1.04-1.93) in the univariate analysis and 1.49 (95% 0.42-5.30) in the multivariate analysis.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Review Article Source Type: research